Compare CHT & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHT | TEVA |
|---|---|---|
| Founded | 1996 | 1901 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5B | 40.5B |
| IPO Year | 2003 | 1996 |
| Metric | CHT | TEVA |
|---|---|---|
| Price | $45.37 | $38.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.63 |
| AVG Volume (30 Days) | 175.9K | ★ 4.1M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | $3.23 | $2.97 |
| P/E Ratio | $26.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.28 | $18.21 |
| 52 Week High | $46.48 | $38.37 |
| Indicator | CHT | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 78.34 | 57.51 |
| Support Level | $41.90 | $30.42 |
| Resistance Level | $45.10 | $38.37 |
| Average True Range (ATR) | 0.42 | 1.04 |
| MACD | 0.19 | -0.12 |
| Stochastic Oscillator | 96.92 | 64.75 |
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company's reportable segments are: Consumer Business, Enterprise Business, International Business, and Others. The majority of its revenue comes from the Consumer Business, which focuses on individual and home-centric businesses, such as mobile, fixed broadband, Wi-Fi, IPTV (MOD), and OTT services. The Enterprise business offers IDC, cloud, cybersecurity, 5G, AIoT, data, AI, enterprise digital transformation, and system integration services to businesses, and the International business segment represents services offered to international customers. Geographically, the company generates maximum revenue from its business in Taiwan.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.